SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American family physician 2021-08, Vol.104 (2), p.206-206
1. Verfasser:	Shaughnessy, Allen F
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - analogs & derivatives Glucagon-Like Peptides - therapeutic use Glucose Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Immunoglobulin Fc Fragments - administration & dosage Immunoglobulin Fc Fragments - therapeutic use Meta-analysis Metformin - administration & dosage Metformin - therapeutic use Mortality Patient Reported Outcome Measures Patients Peptides Randomized Controlled Trials as Topic Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Sodium-Glucose Transporter 2 Inhibitors - administration & dosage Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0002-838X 1532-0650